UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Clinical pharmacology and therapeutics, 2004-05, Vol.75 (5), p.455-463

2004

Volltextzugriff (PDF)

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

Clinical pharmacology and therapeutics, 2004-08, Vol.76 (2), p.167-177

2004

Volltextzugriff (PDF)

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

British journal of clinical pharmacology, 2002-11, Vol.54 (5), p.472-477

2002

Volltextzugriff (PDF)

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

The American journal of cardiology, 2003, Vol.91 (1), p.33-41

2003

Volltextzugriff (PDF)

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia

Current medical research and opinion, 2008-09, Vol.24 (9), p.2575-2585

2008

Volltextzugriff (PDF)

A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness

Journal of clinical pharmacology, 2003-09, Vol.43 (9), p.943-967

2003

Volltextzugriff (PDF)

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

Clinical therapeutics, 2003-02, Vol.25 (2), p.459-471

2003

Volltextzugriff (PDF)

Effect of itraconazole on the pharmacokinetics of rosuvastatin

Clinical pharmacology and therapeutics, 2003-04, Vol.73 (4), p.322-329

2003

Volltextzugriff (PDF)

Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics

Journal of clinical pharmacology, 2005-08, Vol.45 (8), p.927-934

2005

Volltextzugriff (PDF)

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

British journal of clinical pharmacology, 2003-01, Vol.55 (1), p.94-99

2003

Volltextzugriff (PDF)

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics

Current medical research and opinion, 2008-04, Vol.24 (4), p.1231-1235

2008

Volltextzugriff (PDF)

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

Clinical pharmacology and therapeutics, 2005-10, Vol.78 (4), p.330-341

2005

Volltextzugriff (PDF)

Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia

Coronary artery disease, 2004-03, Vol.15 (2), p.115-123

2004

Volltextzugriff (PDF)

The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive

British journal of clinical pharmacology, 2004-03, Vol.57 (3), p.279-286

2004

Volltextzugriff (PDF)

No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers

Journal of clinical pharmacology, 2002-12, Vol.42 (12), p.1352-1357

2002

Volltextzugriff (PDF)

Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor

The American journal of cardiology, 2001-03, Vol.87 (5), p.28-32

2001

Volltextzugriff (PDF)

Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium

The journal of clinical psychiatry, 1996-05, Vol.57 (5), p.204

1996

Volltextzugriff (PDF)

No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor

Journal of clinical pharmacology, 2002-10, Vol.42 (10), p.1116-1121

2002

Volltextzugriff (PDF)

Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion

Clinical pharmacology and therapeutics, 1990-04, Vol.47 (4), p.499-503

1990

Volltextzugriff (PDF)

Mechanism by which hydralazine increases propranolol bioavailability

Clinical pharmacology and therapeutics, 1984-04, Vol.35 (4), p.447-453

1984

Volltextzugriff (PDF)

Rosuvastatin pharmacokinetics and pharmacogenetics in white and asian subjects residing in the same environment. Commentary

Clinical pharmacology and therapeutics, 2005, Vol.78 (4), p.330-341

2005

Volltextzugriff (PDF)

Age and ceftriaxone kinetics

Clinical pharmacology and therapeutics, 1984-01, Vol.35 (1), p.19-25

1984

Volltextzugriff (PDF)

Effects of nadolol and propranolol on plasma lidocaine clearance

Clinical pharmacology and therapeutics, 1984-11, Vol.36 (5), p.584-587

1984

Volltextzugriff (PDF)

Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca

The American journal of cardiology, 2001-03, Vol.87 (5), p.28-32

2001

Volltextzugriff (PDF)

Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon

Clinical pharmacology and therapeutics, 1984-07, Vol.36 (1), p.105-115

1984

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(44)
Dissertationen
(1)

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Thema

Science & Technology
(37)
Life Sciences & Biomedicine
(36)
Humans
(34)
Male
(26)
Adult
(25)
Biological And Medical Sciences
(23)
Medical Sciences
(23)
Pharmacology & Pharmacy
(22)
Pharmacology. Drug Treatments
(21)
Female
(17)
Middle Aged
(17)
Rosuvastatin Calcium
(16)
Aged
(12)
Drug Interactions
(12)
Area Under Curve
(11)
Fluorobenzenes - Pharmacokinetics
(11)
General And Cellular Metabolism. Vitamins
(10)
Cross-Over Studies
(9)
Hydroxymethylglutaryl-Coa Reductase Inhibitors - Pharmacokinetics
(9)
Double-Blind Method
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia

A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

Effect of itraconazole on the pharmacokinetics of rosuvastatin

Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia

The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive

No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers

Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor

Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium

No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor

Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion

Mechanism by which hydralazine increases propranolol bioavailability

Rosuvastatin pharmacokinetics and pharmacogenetics in white and asian subjects residing in the same environment. Commentary

Age and ceftriaxone kinetics

Effects of nadolol and propranolol on plasma lidocaine clearance

Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor11CRESTOR is a trademark, the property of AstraZeneca PLC. Research discussed in this article was supported by AstraZeneca

Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon

Suchergebnisse filtern